CINXE.COM
Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years
<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults."> <meta property="og:title" content="Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years"> <meta name="twitter:description" content="According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults."> <meta name="twitter:title" content="Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css"> <!-- Editor Styles --> <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style> <!-- Added by GoogleAnalytics4 integration --> <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script> <!-- /Added by GoogleAnalytics4 integration --> <link rel="canonical" href="https://oxfordglobal.com/discovery-development/resources/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/FDA%20approves%20Bristol%20Myer%20Squibb%E2%80%99s%20first%20novel%20schizophrenia%20drug%20in%2035%20years.png"> <meta property="og:image:width" content="800"> <meta property="og:image:height" content="600"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/FDA%20approves%20Bristol%20Myer%20Squibb%E2%80%99s%20first%20novel%20schizophrenia%20drug%20in%2035%20years.png"> <meta property="og:url" content="https://oxfordglobal.com/discovery-development/resources/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="discovery-development"> <div class="body-wrapper hs-content-id-177028096592 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/discovery-development" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/discovery-development/events/discovery-development-europe-2025" class="pill center"> <div class="b">Discovery & Development Europe 2025</div> <div class="heading-smallcaps"> 01 - 02 Jul 2025 | Basel, Switzerland </div> </a> <a href="/discovery-development/events/discovery-development-us-2025" class="pill center"> <div class="b">Discovery & Development US 2025</div> <div class="heading-smallcaps"> 02 - 03 Oct 2025 | San Diego, CA </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10"> <!-- Individual Online Activity --> <div class="online-activity"> <a href="/discovery-development/online#Controlled%20Release%20Formulations" class="cta" target="_blank"> <h3 class="other-resources">26/06/24 - Controlled Release Formulations</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>We empower scientific decision-makers from the world’s most innovative biopharma organisations to make informed pipeline decisions in early R&D, accelerating their route from target ID to novel clinical candidate.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>Our community extends across the entire early R&D ecosystem, including biopharma, solution providers, start-ups, academics, and investors.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>Scientific & technical insights on the latest targets, platforms and processes impacting drug discovery & development.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Discovery & Development Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/discovery-development/resources/biomedgpt-adopting-a-generalist-approach-to-biomedical-ai" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery%20and%20Development/BiomedGPT%20Adopting%20a%20Generalist%20Approach%20to%20Biomedical%20AI%20.png" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/discovery-development/resources/biomedgpt-adopting-a-generalist-approach-to-biomedical-ai">BiomedGPT: Adopting a Generalist Approach to Biomedical AI </a> </h3> <div class="resource-abstract"> <span class="resource-date">11/11/24 - </span> BiomedGPT, a versatile AI tool used for biomedical research demonstrated impressive results across a wide range of healthcare tasks. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/discovery-development/resources/the-application-of-rnai-therapeutics-for-cardiovascular-disease-treatment">07/11/24 - The Application of RNAi Therapeutics for Cardiovascular Disease Treatment</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/discovery-development/resources/ai-ml-advancements-in-drug-formulation-the-potential-of-self-driving-labs">16/10/24 - AI/ML Advancements in Drug Formulation – The Potential of Self-Driving Labs </a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/discovery-development/resources/sponsored/case-studies/ardigen/advancing-drug-discovery-through-innovative-technologies-strategic-collaboration"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/Advancing%20Drug%20Discovery%20Mock%20Up.png" class="sponsor-resource-bubble-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Advancing Drug Discovery Through Innovative Technologies & Strategic Collaboration </h3> <div class="resource-abstract"> A Concise Report Featuring Insights From The Prominent Thought Leaders Of Discovery & Automate 2024 </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Regulatory | Industry Spotlights & Insight Articles </div> <h1 class="heading"> Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years </h1> <div class="byline"> Edited by Lucia Simmen | 02 October 2024 </div> <div class="abstract"> According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/FDA%20approves%20Bristol%20Myer%20Squibb%E2%80%99s%20first%20novel%20schizophrenia%20drug%20in%2035%20years.png" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p style="text-align: justify;"><strong>Introduction</strong></p> <p style="text-align: justify;">Schizophrenia is a highly complex condition, affecting 3.5 million people in the USA. The condition presents a range of symptoms, including psychosis, social withdrawal, lack of motivation, poor memory, and difficulty focusing. Despite existing treatments, many patients experience limited relief or intolerable side effects, <a href="https://news.bms.com/news/details/2024/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-COBENFY-xanomeline-and-trospium-chloride-a-First-In-Class-Muscarinic-Agonist-for-the-Treatment-of-Schizophrenia-in-Adults/default.aspx" rel="noopener" target="_blank">with up to 60% of people not achieving adequate symptom control</a>.</p> <p style="text-align: justify;">Schizophrenia is also characterised by unpredictable progression and variability in patient response to current therapies. It is estimated that 1.6 million patients in the USA are receiving treatment for schizophrenia. Yet, three<a href="https://www.cnbc.com/2024/09/26/fda-approves-bristol-myers-squibbs-schizophrenia-drug.html" rel="noopener" target="_blank"> quarters of these patients discontinue their medication within the first 18 months due to issues with efficacy or tolerance</a>. This demonstrates the urgent need for new treatment options to better address the diverse needs of those living with the condition.</p> <p style="text-align: justify;"><strong>Cobenfy</strong></p> <p style="text-align: justify;">In a significant milestone, the US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s new drug, Cobenfy, marking the first novel treatment for schizophrenia in over three decades. Cobenfy, a first-in-class muscarinic agonist (a parasympathomimetic drug), represents an innovative approach to treating schizophrenia. </p> <p style="text-align: justify;">Chris Boerner, CEO of Bristol Myers Squibb, further emphasised the significance of this approval: “After more than 30 years, there is now an entirely new pharmacological approach for schizophrenia—one that has the potential to change the treatment paradigm.”</p> <p style="text-align: justify;">Current schizophrenia treatments primarily target dopamine receptors, focusing on managing psychosis and hallucinations but often leading to significant side effects such as motor control issues. Whereas Cobenfy, adopts a novel approach by selectively targeting M1 and M4 receptors, these receptors <a href="https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2023.1124333/full" rel="noopener" target="_blank">reduce the severity of positive and negative cognitive symptoms associated with schizophrenia</a> without affecting the dopamine system. </p> <p style="text-align: justify;"><strong>Related: </strong></p> <ul> <li style="text-align: justify;"><a href="https://oxfordglobal.com/discovery-development/resources/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments" rel="noopener" target="_blank">Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments</a></li> <li style="text-align: justify;"><a href="https://oxfordglobal.com/discovery-development/resources/alzheimers-brain-awareness-month-spotlight-how-amphista-therapeutics-is-tackling-neurological-disorders" rel="noopener" target="_blank">Alzheimer's & Brain Awareness Month Spotlight: How Amphista Therapeutics is Tackling Neurological Disorders</a></li> <li style="text-align: justify;"><a href="https://oxfordglobal.com/discovery-development/resources/spheroids-assembloids-could-unlock-high-throughput-screening-of-neuro-drugs" rel="noopener" target="_blank">Spheroids, Assembloids Could Unlock High Throughput Screening of Neuro Drugs</a></li> </ul> <p style="text-align: justify;">The FDA’s decision to approve Cobenfy was based on robust data from the EMERGENT clinical program, which consisted of three placebo-controlled efficacy and safety trials that demonstrated the long-term safety and tolerability of Cobenfy for up to one year. However, several patients experienced side effects such as nausea, vomiting, and hypertension.</p> <p style="text-align: justify;"><strong>Future Directions</strong></p> <p style="text-align: justify;">As the first drug of its kind to be approved, Cobenfy sets Bristol Myers Squibb ahead of competitors such as AbbVie and Neurocrine Biosciences, who are in the mid-stages of developing treatments targeting the <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006961/" rel="noopener" target="_blank">muscarinic pathway</a>. With analysts predicting that <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-bristol-myers-schizophrenia-drug-2024-09-26/" rel="noopener" target="_blank">Cobenfy will generate $2.5 billion in sales by 2030</a>, it is positioned to become a major player in the schizophrenia treatment market.</p> <p style="text-align: justify;">Bristol Myers Squibb plans to explore Cobenfy’s potential in treating other neuropsychiatric symptoms including bipolar mania. Additionally, ongoing studies aim to evaluate Cobenfy’s efficacy as an add-on therapy for schizophrenia patients who do not respond adequately to existing antipsychotics. Furthermore, there are plans to investigate Cobenfy’s use in treating psychosis associated with Alzheimer’s disease, with trial results expected in 2026.</p> <p style="text-align: justify;"><strong>Conclusion</strong></p> <p style="text-align: justify;">In summary, Cobenfy’s approval signals a shift in the treatment landscape for schizophrenia, offering hope to patients who have struggled to find effective therapies that suit their needs. This breakthrough may also inspire <a href="https://oxfordglobal.com/discovery-development/events/discovery-us-2024" rel="noopener" target="_blank">further innovation in the neuropsychiatric space</a>, encouraging other pharmaceutical companies to focus on the development of novel treatments for complex mental health disorders.</p> <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/discovery-development/resources/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Copy%20of%20Featured%20Image%20(6).png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/discovery-development/resources/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments"> <h4> Beyond Traditional Therapeutics: How Digital Therapeutics Reshape Neurological and Neuropsychiatric Treatments </h4> <div class="abstract"> Two case studies show how digital therapeutics can potentially treat neurological and neuropsychiatric conditions, areas where conventional therapeutics have encountered obstacles. </div> <div class="read-more"> <a href="/discovery-development/resources/beyond-traditional-therapeutics-how-digital-therapeutics-reshape-neurological-and-neuropsychiatric-treatments" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/discovery-development/resources/university-of-pennsylvania-and-fast-to-develop-aav-gene-therapy-for-angelman-syndrome"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/University%20of%20Pennsylvania%20and%20FAST%20to%20Develop%20AAV%20Gene%20Therapy%20for%20Angelman%20Syndrome.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/discovery-development/resources/university-of-pennsylvania-and-fast-to-develop-aav-gene-therapy-for-angelman-syndrome"> <h4> University of Pennsylvania and FAST to Develop AAV Gene Therapy for Angelman Syndrome </h4> <div class="abstract"> The collaboration hopes to develop a AAV gene therapy for rare genetic disease Angelman syndrome. </div> <div class="read-more"> <a href="/discovery-development/resources/university-of-pennsylvania-and-fast-to-develop-aav-gene-therapy-for-angelman-syndrome" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things Discovery & Development </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177049184347">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script> <!-- HubSpot performance collection script --> <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script> <!-- Start of HubSpot Analytics Code --> <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/discovery-development\/resources\/cobenfy-a-critical-breakthrough-in-schizophrenia-treatment-in-over-30-years"]); _hsq.push(["setPageId", "hubdb-177028096592-7642658-180016230914"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177028096592-7642658-180016230914", "legacyPageId": "hubdb-177028096592-7642658-180016230914", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177028096592, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script> <!-- End of HubSpot Analytics Code --> <script type="text/javascript"> var hsVars = { render_id: "380ffb31-6768-4293-b28b-58480bfa0447", ticks: 1732336762323, page_id: 177028096592, dynamic_page_id: "hubdb-177028096592-7642658-180016230914", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177028096592-7642658-180016230914", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>